More recently, the authors proposed the use of such therapeutic activation of ERK1/2 in STAT5‐driven B‐ALL based on the increased lifespan observed in patient‐derived xenografted mice treated with the DUSP1/6 inhibitor BCI‐215 to activate ERK1/2 [28]. This evidence concerns the gene MAPK3 and acute lymphoblastic leukemia.